Key result
5-fluorouracil (5-FU) treatment resulted in a 1.6% overall incidence of cardiopathy, with a significantly higher risk in patients with a history of previous cardiopathy (4.5% vs 1.1%).
Why the study?
What is the incidence of cardiotoxicity in patients receiving 5-fluorouracil chemotherapy for neoplasms?
Population
1083 patients treated with 5-fluorouracil for various kinds of neoplasm
Design
Cohort
Authors
Loading...
Supports pre-5-FU cardiac risk assessment; leaves open whether targeted monitoring alters outcomes.
Observational (n=1,083)
What is the incidence of cardiotoxicity in patients receiving 5-fluorouracil chemotherapy for neoplasms?
5-fluorouracil chemotherapy is associated with a 1.6% incidence of cardiotoxicity, which is significantly higher (4.5%) in patients with pre-existing cardiac disease.
Labianca et al. (1982) conducted an observational in Neoplasm (n=1,083). 5-fluorouracil (5-FU) was evaluated on 5-FU cardiopathy (anginous crises or myocardial infarction). 5-fluorouracil (5-FU) treatment resulted in a 1.6% overall incidence of cardiopathy, with a significantly higher risk in patients with a history of previous cardiopathy (4.5% vs 1.1%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: